SLC5A2 and type 1 diabetes mellitus: On the other hand, a recent meta-analysis of 16 randomized controlled trials in 7192 people with type 1 diabetes showed that the addition of SGLT-2 inhibitors reduced the glycated hemoglobin (HbA1c), fasting plasma glucose, mean amplitude of glucose excursions, and total insulin dosage, while not reducing the risk of hypoglycemia.